Tenofovir Disoproxil Fumarate + Emtricitabine

Tenofovir disoproxil fumarate with emtricitabine is a fixed-dose combination antiretroviral marketed most familiarly as Truvada, along with numerous generic equivalents. It joins two drugs from the nucleoside and nucleotide reverse-transcriptase inhibitor classes: emtricitabine, a synthetic cytidine analogue, and tenofovir disoproxil fumarate, an orally absorbed prodrug that the body converts to tenofovir, an analogue of an adenosine nucleotide. Both compounds interrupt the reverse-transcriptase step through which the human immunodeficiency virus turns its RNA into DNA, and pairing them in one pill supports once-daily dosing ^[3].

The combination serves two purposes. As part of a complete antiretroviral regimen, usually alongside a third agent such as an integrase or non-nucleoside inhibitor, it helps suppress HIV replication and preserve immune function; a randomized trial in previously untreated patients found that a tenofovir and emtricitabine backbone with efavirenz produced greater and more durable viral suppression, larger CD4 gains, and fewer treatment-limiting side effects than an older zidovudine and lamivudine backbone ^[3]. Its second use is prevention: taken by HIV-negative people at higher risk, it reduces the chance of infection, an approach known as pre-exposure prophylaxis.

Evidence for prevention came from large randomized trials. The iPrEx study, in men and transgender women who have sex with men, reported that daily oral emtricitabine and tenofovir lowered new HIV infections by about 44 percent overall, with far greater protection among participants who took the drug consistently, as judged by measured blood drug levels ^[1]. The Partners PrEP trial, in serodiscordant heterosexual couples in Kenya and Uganda, found the combination cut HIV-1 acquisition by roughly 75 percent ^[2]. On the strength of such data the fixed-dose pill was approved for HIV treatment in 2004 and became the first medication authorized for pre-exposure prophylaxis in 2012.

The combination appears on the World Health Organization's Model List of Essential Medicines, and after key patents lapsed around 2020 it became widely available as inexpensive generics. It is one of two main tenofovir and emtricitabine products; the other pairs emtricitabine with the newer prodrug tenofovir alafenamide. Because tenofovir disoproxil fumarate can affect kidney function and bone mineral density over time, and because effective prevention depends on good adherence and a confirmed HIV-negative status, the medicine is prescribed and monitored by clinicians. Reported adverse effects include nausea, headache, and, less often, kidney injury or, as a class caution for nucleoside analogues, lactic acidosis and liver problems.

This is a prescription combination with two boxed warnings; a class risk of lactic acidosis with liver enlargement, and severe flares of hepatitis B if the drug is stopped in someone who is co infected. The tenofovir disoproxil form can strain the kidneys, occasionally causing tubular damage, and can lower bone mineral density over time. For PrEP it is essential to confirm the person is HIV negative before starting and to keep testing, because taking only these two drugs while unknowingly infected can breed resistance. Everyday side effects are usually mild; nausea, headache and diarrhea that often settle. Avoid stacking it with other kidney stressing drugs.

This fixed-dose antiretroviral was developed by Gilead Sciences and approved by the US FDA in 2004 under the brand name Truvada, combining two of the company's nucleoside and nucleotide reverse-transcriptase inhibitors in a single daily tablet. Emtricitabine, a cytidine analogue, and tenofovir disoproxil fumarate, an orally absorbed prodrug of the adenine nucleotide analogue tenofovir, had each been approved individually shortly before, and their pairing quickly became a backbone of combination therapy for HIV infection.

The drug's most historically significant chapter came in 2012, when, on the strength of prevention trials such as iPrEx, the FDA approved Truvada as the first medication for pre-exposure prophylaxis, a landmark in HIV prevention that allowed HIV-negative people at risk to substantially lower their chance of acquiring the virus. It later became available as low-cost generics, broadening global access, and its role has since been studied against newer agents. It appears on the World Health Organization's list of essential medicines.

Tenofovir disoproxil fumarate with emtricitabine is widely considered one of the most important medicines in the history of the HIV epidemic, valued both as a durable treatment backbone and as the drug that made pre-exposure prophylaxis a reality. As PrEP it has been shown in large trials and real-world programs to dramatically reduce new infections, with protection tracking closely to how consistently it is taken, and it has become a cornerstone of public-health strategies to end HIV transmission.

Its long record, once-daily dosing, and availability as inexpensive generics have made it accessible to millions worldwide. Users and clinicians appreciate that adherence, more than anything, determines its effectiveness. In candor, the tenofovir disoproxil formulation can, in a minority of users, affect kidney function and bone mineral density, which prompted development of the newer tenofovir alafenamide formulation; head-to-head trials found the two comparably effective for prevention, with the newer version gentler on kidney and bone markers.